![North American Neuromodulation Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Technology [External Neuromodulation and Internal Neuromodulation], Application, and End User and Country- Product Image](http://www.researchandmarkets.com/product_images/11575/11575898_500px_jpg/north_american_neuromodulation_market.jpg)
According to the latest study on‘Neuromodulation Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Technology, Application, End User, and Country’ the North AmericaNeuromodulationmarket was valued at US$ 3,029.72 million in 2019 and is projected to reach US$ 6,612.00 million by 2027; it is expected to grow at a CAGR of 10.6% during 2020-2027. The report highlights the trends prevailing in the North Americaneuromodulation market and the factors driving the market along with those that act as deterrents to its growth.
Based on technology, the neuromodulation market is segmented external (non-invasive) neuromodulation and internal neuromodulation. In 2019, the internal neuromodulation segment accounted for the largest share of the North America neuromodulation market. The growth of the segment attributes to growth of internal neuromodulation segment is attributed to increasing product launches in the market, the rising product innovation for neuromodulation devices and growing developments in neuromodulation technology are some of the primary factors contributing to the dominance of the segment in the North America Neuromodulation market. Additionally, the outbreak of the COVID-19 pandemic has highly affected the countries in the North American region.
Abbott, Boston Scientific Corporation, Medtronic, NeuroPace, Inc., NeuroSigma, Inc., NEVRO CORP, Synapse Biomedical Inc., Soterix Medical Inc, Integer Holdings Corporation, and Magstim. are among the prominent players present in the neuromodulation market. The market players are focused on mergers and acquisitions to sustain their position in the market. For instance, in September 2020Boston Scientific announced the European launch of the WaveWriter Alpha portfolio of Spinal Cord Stimulator (SCS) Systems. The portfolio, consisting of four MRI conditional, Bluetooth-enabled implantable pulse generators (IPGs), offers expanded personalization based on patient needs, including rechargeable and non-rechargeable options, and access to waveforms that can cover multiple areas of pain.Reasons to Buy
Based on technology, the neuromodulation market is segmented external (non-invasive) neuromodulation and internal neuromodulation. In 2019, the internal neuromodulation segment accounted for the largest share of the North America neuromodulation market. The growth of the segment attributes to growth of internal neuromodulation segment is attributed to increasing product launches in the market, the rising product innovation for neuromodulation devices and growing developments in neuromodulation technology are some of the primary factors contributing to the dominance of the segment in the North America Neuromodulation market. Additionally, the outbreak of the COVID-19 pandemic has highly affected the countries in the North American region.
Abbott, Boston Scientific Corporation, Medtronic, NeuroPace, Inc., NeuroSigma, Inc., NEVRO CORP, Synapse Biomedical Inc., Soterix Medical Inc, Integer Holdings Corporation, and Magstim. are among the prominent players present in the neuromodulation market. The market players are focused on mergers and acquisitions to sustain their position in the market. For instance, in September 2020Boston Scientific announced the European launch of the WaveWriter Alpha portfolio of Spinal Cord Stimulator (SCS) Systems. The portfolio, consisting of four MRI conditional, Bluetooth-enabled implantable pulse generators (IPGs), offers expanded personalization based on patient needs, including rechargeable and non-rechargeable options, and access to waveforms that can cover multiple areas of pain.Reasons to Buy
- Saves and reduces time required for carrying out entry-level research by identifying the growth, size, leading players, and segments in the North American neuromodulation Market
- Highlights key business priorities to assist companies in order to realign their business strategies
- Highlights key findings and recommendations of crucial progressive industry trends in the North American neuromodulation Market, thereby allowing players across the value chain to develop effective long-term strategies
- Develops/modifies business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinizes in-depth North American Market trends and outlook coupled with the factors driving the Market, as well as those hindering it
- Enhances the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution
Table of Contents
1. Introduction
2. Neuromodulation Market - Key Takeaways
3. North America Neuromodulation- Market Landscape
4. Neuromodulation Market - Key Market Dynamics
5. Neuromodulation Market Analysis - by Technology
6. Neuromodulation Market Analysis - by Application
7. Neuromodulation Market Analysis - by End User
8. Neuromodulation Market Analysis and Forecasts to 2027 - Regional Analysis
9. Company Profiles
10. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott
- Boston Scientific Corporation
- Medtronic
- NeuroPace, Inc.
- NeuroSigma, Inc.
- NEVRO CORP.
- Synapse Biomedical Inc.
- Soterix Medical Inc
- Integer Holdings Corporation
- Magstim
